Yang CH - Search Results

1

A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer.

Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS, Yang CH. Lin CC, et al. Among authors: yang ch. Anticancer Res. 2007 Jan-Feb;27(1B):641-5. Anticancer Res. 2007. PMID: 17348454 Free article. Clinical Trial.

2

A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.

Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH. Hsu CH, et al. Among authors: yang ch. Anticancer Res. 2002 Nov-Dec;22(6B):3621-7. Anticancer Res. 2002. PMID: 12552966 Clinical Trial.

3

Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.

Yang CH, Chen YC, Kuo ML. Yang CH, et al. Anticancer Res. 2003 May-Jun;23(3B):2519-23. Anticancer Res. 2003. PMID: 12894535

4

Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13.

Chie WC, Yang CH, Hsu C, Yang PC. Chie WC, et al. Among authors: yang ch, yang pc. Qual Life Res. 2004 Feb;13(1):257-62. doi: 10.1023/B:QURE.0000015295.74812.06. Qual Life Res. 2004. PMID: 15058806

5

Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.

Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL. Lu YS, et al. Among authors: yang ch. Hepatogastroenterology. 2004 May-Jun;51(57):815-9. Hepatogastroenterology. 2004. PMID: 15143923 Clinical Trial.

6

Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials.

Kuo SH, Yang CH, Yu CJ, Hsu C, Cheng AL, Yang PC. Kuo SH, et al. Among authors: yang ch, yang pc. Lung Cancer. 2005 May;48(2):275-80. doi: 10.1016/j.lungcan.2004.10.004. Epub 2004 Dec 15. Lung Cancer. 2005. PMID: 15829329

7

Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.

Yang CH, Chen MC, Cheng AL, Hsu CH, Yeh KH, Yu YC, Whang-Peng J, Yang PC. Yang CH, et al. Among authors: yang pc. Oncology. 2005;68(4-6):350-5. doi: 10.1159/000086974. Epub 2005 Jul 11. Oncology. 2005. PMID: 16020962 Clinical Trial.

8

Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.

Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, Yang PC. Yang CH, et al. Among authors: yang pc, yang cs. Cancer Res. 2005 Aug 1;65(15):6943-9. doi: 10.1158/0008-5472.CAN-05-0641. Cancer Res. 2005. PMID: 16061679

9

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.

Su WP, Yang CH, Yu CJ, Shih JY, Hsu C, Yang PC. Su WP, et al. Among authors: yang ch, yang pc. J Formos Med Assoc. 2005 Aug;104(8):557-62. J Formos Med Assoc. 2005. PMID: 16193176

10

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.

Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Lin CC, et al. Among authors: yang ch. Invest New Drugs. 2007 Feb;25(1):77-84. doi: 10.1007/s10637-006-9004-9. Epub 2006 Aug 26. Invest New Drugs. 2007. PMID: 16937079 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,189 results

Search Page

Filters